Veracyte Inc. (VCYT)
NASDAQ: VCYT · Services-Medical Laboratories · South San Francisco, CA
Our rating: Positive
Positive reaffirmed at $46.41, moderate conviction, August 11, 2026.
Breaks if: Revenue growth rate falls below 10% year-over-year in two consecutive quarterly reports within the next twelve months — at that point the premium multiple loses its primary support and the call moves toward Cautious. On the upside, the call would upgrade toward Conviction if revenue growth sustains at or above 15% for three consecutive quarters while FCF margin expands to 28% or above, signaling that operating leverage is compounding alongside top-line durability.
Key figures
| Market value | $2.0B |
|---|---|
| Revenue, last 12 months | $582M |
| Net income, last 12 months | $127M |
| Free cash flow, last 12 months | $162M |
| Price to earnings | 16.0× |
| Free cash flow yield | 8.0% |
| Dividend yield | 0.0% |
| Operating margin | 17.1% |
| Return on equity | 9.4% |
| Beta to the S&P 500 | 1.66 |
| Volatility, annualized | 68.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $152M | 15.1% | $0.38 | $38M |
| June 30, 2026 | $150M | 15.5% | $0.31 | $43M |
| March 31, 2026 | $139M | 21.5% | $0.35 | $32M |
| December 31, 2025 | $141M | 18.5% | $0.50 | $49M |
| September 30, 2025 | $132M | 13.8% | $0.24 | $42M |
| June 30, 2025 | $130M | 13.8% | $-0.01 | $32M |
| March 31, 2025 | $114M | 18.2% | $0.09 | $4M |
| December 31, 2024 | $119M | 20.8% | $0.06 | $20M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.17B: Claude 42%, Gemini 65%, Mistral 30%
- Diluted earnings per share are at least $0.50: Claude 45%, Gemini 25%, Mistral 15%
- Free cash flow for the quarter is at least $0.05B: Claude 48%, Gemini 70%, Mistral 42%
13 ledger entries and 53 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.